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The  debate  on  the  relevance  of rotavirus  vaccine  to immunization  program  in India,  where 27 million  chil-
dren  are  born  every  year,  rages  on.  We  synthesized  the  issues  raised  during  these  debates  and  reviewed
the current  literature  to  identify  themes  that  could  inform  public  health  policy  decision.  The  paradigm
we  used  integrated  disease  burden  data,  host  and  environmental  factors,  vaccine  efﬁcacy,  immunization
program  issues,  and  economic  considerations.  Our synthesis  reveals  that  substantive  country  speciﬁc
information  on disease  burden  and  economic  impact  of  rotavirus  illness  in  India  is  constrained  by lack
of  public  discussion  and  qualitative  studies  on mothers’  perceptions  of  the vaccine  in concern.  The  need
to  improve  the performance  of  current  immunization  program  against  six major  vaccine  preventable
diseases  (tuberculosis,  diphtheria,  tetanus,  pertussis,  polio,  and  measles)  is  often  cited as a priority  over
introduction  of rotavirus  vaccine.  Health  in India  being  a state  subject,  we  emphasize  that  the  states
which  are in  a position  to reap  the  beneﬁt  of rotavirus  vaccine,  due  to their  good  immunization  program
performance,  should  not  be restrained  from  doing  so.  Meanwhile,  the  poorly  performing  states  should
step  up  their  vaccination  program  and  increase  immunization  coverage.  Scientiﬁc,  ethical  and  societal
concerns  captured  through  multiple  sources  indicate  that the  introduction  of rotavirus  vaccine  would  be
a good  investment  for India.
© 2014  Published  by Elsevier  Ltd.  This is an  open  access  article  under  the  CC  BY-NC-ND  license. Introduction
Rotavirus infection occurs worldwide in children under ﬁve
ears of age. The infection may  remain asymptomatic, cause self-
imiting watery diarrhea or may  lead to acute gastroenteritis with
ever, vomiting and severe dehydration that may  at times be fatal.
outs of vomiting associated with severe rotavirus gastroenteri-
is (SRVGE) also pose a hurdle to the clinical management of these
ases with oral rehydration salt and sugar solution. Furthermore, no
ntiviral medicine is currently considered as “standard of care” for
RVGE. On the other hand, disease burden and cost implications of
otavirus diarrhea have been estimated to be enormous [1,2]. Due
ttention has therefore been paid by global health policy makers
o tackle this challenging situation. Consequently, many countries
ave introduced rotavirus vaccines in their routine immunization
rogram [3,4] after much deliberation. Key deciding factors for
∗ Corresponding author. Tel.: +91 33 23633373; mobile: +91 9830908475.
E-mail address: pandasamiran@gmail.com (S. Panda).
1 Tel.: +1 310 825 6381.
ttp://dx.doi.org/10.1016/j.vaccine.2014.03.037
264-410X/© 2014 Published by Elsevier Ltd. This is an open access article under the CC (http://creativecommons.org/licenses/by-nc-nd/3.0/).
introducing rotavirus vaccine in low-income countries have been
cost of immunization, ﬁnancial support from global alliance for vac-
cines and immunization (GAVI) and long-term sustainability of the
program following withdrawal of external assistance [5]. In India,
the issue continues to be debated. While one group of discussants
opines that India should [6] introduce the vaccine in her routine
immunization program, others take a contrary stance [7].
India’s national immunization program has evolved since the
1970s (Fig. 1) leading to the introduction of some vaccines
and dropping of others based on scientiﬁc evidence and public
health considerations. The rotavirus debate pivots on vaccine efﬁ-
cacy. While the indigenous Rotavac2 vaccine tested in India is
being challenged [8], Rotarix3 and Rotateq4 – two  vaccines that
have undergone clinical trials in many developed and developing
countries [9–11] – have not undergone trial in India. However,
the latter two are currently available through the private health
2 Developed from New Delhi strain (116E) isolated from asymptomatic neonates.
3 Monovalent vaccine that used a human strain.
4 WC-3-based multivalent human-bovine reassortant vaccine.
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ector. Some health professionals have questioned whether a vac-
ine should be our only strategy to tackle rotavirus disease burden
12].
Our objective was to understand how evidence was  used by
ifferent discussants in the aforementioned arguments and to inte-
rate scientiﬁc ﬁndings with societal and ethical concerns. By
ategorizing these arguments, we also aimed to inform policy mak-
rs in the country for evidence based action.
. Method
.1. Literature review
Based on our initial understanding of the debate two key areas
ere selected for literature review, (a) ‘epidemiology’ and (b) ‘vac-
ine’; another subsidiary area chosen for review was  ‘debate’. We
dopted a thorough search strategy, followed by data screening.
.1.1. Search strategy
We  searched PubMed and Embase (two bibliographic databases)
sing identical search terms to retrieve articles on identiﬁed areas
ublished in English till September 2013. We  did not specify any
tart-time of publication while conducting this search. Under ‘epi-
emiology’ we searched PubMed with ‘rotavirus’ (‘rotavirus’ OR
rotavirus infections’) as Medical Subject Heading (MeSH) major
erm, paired with MeSH subheading term ‘epidemiology’ and text
ord ‘India’. For Embase search, ‘rotavirus’ and ‘epidemiology’ as
ubject heading terms were paired with the text word ‘India’.
A similar search strategy as above was followed for ‘vaccine’
ith a single change: the term ‘epidemiology’ was replaced by
eSH major term ‘rotavirus vaccines’ OR ‘vaccines’ OR ‘vaccination’
n PubMed. These three subject heading terms were similarly paireduction of the Expanded Program for Immunization (EPI).
for searching in Embase. Articles highlighting ‘debate’ featured in
our rotavirus vaccine search. However, in order to obtain wider
perspective of the debate, the terms ‘perceptions’, ‘policy’, ‘debate’,
‘importan*’, ‘necess*’ were combined with the terms ‘vaccines’ AND
‘India’, in both bibliographic databases.
Apart from PubMed and Embase, we searched the Cochrane
Library to identify systematic reviews or meta-analyses on
rotavirus vaccine. When searched with rotavirus vaccine as a MeSH
term, two meta-analyses [13,14] were identiﬁed, one published
in 2004 and the other in 2012, conducted by the same group
of authors. Bibliographies of retrieved articles were reviewed for
additional citations and accessed. Experts in the ﬁeld were also con-
sulted to obtain articles that might have been missed in the above
mentioned search.
2.1.2. Data screening
Full texts of the manuscripts were accessed which included arti-
cles, letters and short communications. We  excluded conference
abstracts, studies not focussed on India, rotavirus infection in ani-
mals and articles on clinical management. Duplicates in databases
were sorted and the numbers of articles ﬁnally selected are pre-
sented in Fig. 2. Bibliographies were managed by EndNote (version
5.0.1).
2.2. Analysis
The data for our analyses was  text obtained through the afore-
mentioned search process. The aim in the ﬁrst phase of analyses
was to familiarize ourselves with the various arguments used to
arrive at conclusions. We  read the articles line by line to identify
threads of arguments which we manually coded without hierar-
chy and identiﬁed cognitive contents (Fig. 3). In the next phase
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f analyses we attempted to identify if different scientiﬁc, eco-
omic, societal and ethical perspectives led the discussants to
rrive at dissimilar conclusions from available evidence base. This
equired referring to the original articles that the discussants
sed in building their arguments. Part of this exploration included
dentifying if same evidence was interpreted differently by differ-
nt discussants. We  also took recent and emerging evidence into
ccount.
. Results
.1. Data categorization
Of the 177 articles resulting from the data screening process
Fig. 2), 117 were from the domain of ‘epidemiology’, 39 from
vaccine’ and 21 from ‘debate’. Articles retrieved under ‘debate’
omprised efﬁcacy, adverse events and immunization performance
elated discussion, perceptions of pediatricians toward immuniza-
ion against rotavirus, as well as policy matters. ‘Vaccine’ articles
ncompassed clinical trials, mechanisms of action, and inhibitory
actors related to oral live vaccines, vaccine uptake by general popu-
ation in urban and rural settings, as well as economic issues. Most
f the articles in ‘epidemiology’ were on hospital based studies,arch algorithm.
and only 14 out of 117 articles (12%) described community based
investigations. While 10 community based studies were carried out
over the last decade, the rest were from an earlier time. Apart from
articles referring to rotavirus group A, group B rotavirus studies
(occurring rarely and mostly in adults) also featured in our search.
Nine articles dealing with infrequent rotavirus genotypes of group
A and ﬁve about group B were not included during detailed anal-
ysis and thus a total of 163 articles (103 from ‘epidemiology’, 39
from ‘vaccine’ and 21 from ‘debate’) were analyzed in-depth. Orig-
inal research and review articles were used in the citation for the
present write-up, as deemed appropriate.
The earliest article documenting rotavirus in children in India
appeared from Vellore in Tamilnadu [15] within a year of its ﬁrst
detection in Australia [16]. We  noticed that articles on rotavirus
diarrhea subsequently started appearing from various parts of
the country, including north-eastern states [17–19], all of which
appeared under ‘epidemiology’.
Cognitive contents in articles used for detailed analyses were
arranged into themes as shown in Fig. 3 for synthesizing arguments.
The six emerging themes were – (a) disease burden, (b) host factors
(mother and child), (c) macro-social environment, (d) the agent
(rotavirus) and the vaccine, (e) immunization program issues, and
(f) economic issues.
S. Panda et al. / Vaccine 32S (2014) A162–A170 A165
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.2. Disease burden
Disease burden is presented here under two major headings, (a)
orbidity and (b) mortality due to rotavirus diarrhea in India. Most
f the information under this topic came from facility based studies
20], and we identiﬁed scarcity of data on morbidity and mortality
n communities. As highlighted by some authors [21], commu-
ity based studies are close to true estimates of rotavirus disease
urden and are also representative of circulating strains and
erotypes.
.2.1. Morbidity
A study [22], using data from the Indian Rotavirus Strainurveillance Network (operating through hospitals) and rate of hos-
italizations due to rotavirus diarrhea in a south Indian birth cohort,
stimated that 457,000–884,000 hospital admissions occur in India
nnually due to rotavirus. The same study also estimated that everyg into policy framework.
year rotavirus infection leads to about two  million outpatient visits
in children under-ﬁve years.
We identiﬁed four community based prospective cohort studies,
conducted in the recent past, to assess rotavirus disease morbidity
in the community. One of them, from an urban slum in Vellore,
south India [23], investigated the issue of protection conferred by
prior rotavirus infection to subsequent infections and rotavirus
diarrhea. We  examined three other studies [24–26], one each from
north (Delhi), east (West Bengal) and south (Tamil Nadu) India, that
assessed community based disease burden. In these studies SRVGE
constituted 17–33% of all rotavirus diarrheal episodes. Extrapo-
lation of this information to an Indian birth cohort of 27 million
reveals rotavirus related diarrhea morbidity in the community to
be at least four times higher than what is captured through hospital
based surveillance.
In the rotavirus vaccine debate, some discussants have argued
that the high morbidity associated with rotavirus diarrhea can
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e partially attributed to concomitant enteric infections [12]. A
ecent multi-country investigation on diarrheal disease in infants
nd young children informs us on this issue [27]. This matched
ase–control study estimated burden of disease adjusted for the
ccurrence of asymptomatic colonization with enteric pathogens
ften seen in children living in fecally contaminated environments
28]. Despite a wide array of putative pathogens detected, only a
ew contributed to most attributable moderate-to-severe diarrhea
ases and rotavirus was the prime organism detected in multiple
ge strata in this study [27].
.2.2. Mortality
Studies offer different estimates (from 81,000 to 113,000) of
otavirus deaths in children under-ﬁve years in India. The lower
stimate was generated using the World Health Organization’s
ecommended method [29] and the higher ﬁgure was obtained
n the basis of ﬁndings from million death study that used a
ationally representative survey conducted in community settings
30]. Worldwide rotavirus associated mortality estimated in 2008,
oncurred with this range [31]. Using data from a birth cohort of an
rban slum in south India, national family health survey (NFHS),
ational statistics from WHO  and UNICEF, and Indian Rotavirus
train Surveillance Network, Tate et al. generated a higher mor-
ality range (122,000–153,000) [22]. These studies suggest that
ndia contributes the highest number of rotavirus diarrhea deaths
n children globally. However, some pediatricians have expressed
oncern whether all these deaths could be ascertained solely to
otavirus infection, because bacterial co-infections are known to
nterplay [12] and enhance rotavirus disease severity.
The opponents of rotavirus vaccine in India argued that in efﬁ-
acy trials of currently available rotavirus vaccines, cumulative
ortality was marginally higher among the vaccinated group than
he placebo group [7]. They cited Cochrane review [14] in this
egard. Upon careful reading, we realized that the review actu-
lly reported that protection offered by rotavirus vaccines against
ortality could not be established as the studies were mostly
onducted in low-mortality countries. Furthermore, the Cochrane
eview underlined the importance of these vaccines by highlight-
ng three aspects, (a) effectiveness in reducing rotavirus diarrhea
severe cases and cases of any severity), (b) effectiveness in reduc-
ng all cause diarrhea, and (c) effectiveness in reducing need for
ospitalization due to rotavirus infection.
.3. Host factors (mother and child)
In the debate on rotavirus vaccines, it has been argued that bio-
ogical and behavioral host factors have implications for policy on
accines.
.3.1. Biological factors
Breastfeeding did not have any protective effect against
otavirus diarrhea in an investigation conducted in rural West Ben-
al, India [32]. A research from the neighboring Bangladesh has
nferred that breastfeeding postpones rather than prevents occur-
ence of rotavirus diarrhea in children under-two years age [33].
urther, investigations have been carried out to examine inhibitory
ffect of breast milk on live oral rotavirus vaccine. A study [34]
nvolving breast feeding mothers from India, Vietnam, South Korea
nd USA, detected the highest IgA and neutralizing titers among
ndian mothers against strains present in the vaccines Rotarix,
otateq and Rotavac. This was a concern because neutralizing anti-
ody in mother’s milk might reduce the effectiveness of oral live
otavirus vaccine administered to infants.
The natural history of rotavirus infection in children shows
hat the virus commonly does not infect neonates and infection
ates peak between 3 and 24 months of age [35,36]. The chances of (2014) A162–A170
reinfection and severity of diarrhea is thought to decrease follow-
ing the ﬁrst infection with rotavirus. However, in a community
based study from Vellore [23], levels of reinfection were found to
be quite high, with approximately only 30% of all infections iden-
tiﬁed being primary. Also, protection against moderate or severe
diarrhea reportedly increased with the order of infection but was
found to be only 79% after three infections. Critics of rotavirus
vaccine have cited the above evidence to argue that immunization
against rotavirus, similar to primary rotavirus infections, might
not prove efﬁcacious in the Indian scenario in preventing repeated
rotavirus infections [7].
3.3.2. Behavioral factors
We  could not identify any rotavirus speciﬁc study addressing
host behavioral issues. However, a survey undertaken by UNICEF
[37] in India in 2009 is worth noting in terms of perceptions of
parents vis-à-vis vaccine uptake. In this study, parents of 12–23
months old children with no or partial immunization were inter-
viewed about the reasons for failing to immunize or partially
vaccinating their children. Thirty-six percent of parents living in
urban and 26% in rural areas did not feel the need to vaccinate their
children while approximately 25% parents did not know their chil-
dren could be protected with vaccines. About 11% were unaware
of where to get children immunized. The pattern of response how-
ever differed between urban and rural settings. The reasons cited
for partial immunization comprised lack of knowledge about ‘what
vaccines were needed’ and ‘when those were to be given’. On the
other hand, ‘fear of side effects’ was  one of the major reasons for
‘no’ immunization.
3.4. Macro-social environment
The macro-social issues raised in the rotavirus vaccine debate in
India were (a) sanitary hygiene and access to safe drinking water,
(b) ‘tropical barriers’ to oral vaccines, and (c) physicians’ percep-
tions of vaccination. While physicians’ views can inﬂuence vaccine
dispensation among the public, the other issues (such as microbiota
of gastrointestinal tract in tropical countries) inﬂuence vaccine
uptake at the gut-level.
3.4.1. Infrastructure
Some authors who  favored rotavirus vaccine as the principal
mode of intervention also recognized sanitation, hygiene, and safe
water supply as effective prevention measures against diarrheal
diseases caused by bacteria and parasites [38]. They did not assign
much weight to the above measures for controlling rotavirus gas-
troenteritis due to the ubiquitous presence of the virus in the
developing and developed world. However, others have pointed
out that such infrastructural interventions might indeed be useful
[12,39] to reduce all causes of diarrheal morbidity and mortality,
including that caused by rotavirus. This conviction comes from the
fact that the severity of rotavirus gastroenteritis is inﬂuenced by
the presence of co-infections in the gut, which in turn, is linked
with poor civic infrastructure such as water supply and sewerage
systems.
3.4.2. Physicians’ perceptions
A national survey [40], conducted in 2009–2010 to identify the
predictors of administration and attitude about vaccines includ-
ing rotavirus, revealed that only a tenth of pediatricians had been
routinely administering rotavirus vaccines in India. Unfortunately,
we could neither locate any Indian study on perception of mothers
about rotavirus vaccine nor a public debate.
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.5. The agent (rotavirus) and the vaccines
Diversity of protection (homotypic vs heterotypic) conferred by
ive oral rotavirus vaccine(s) in Indian setting has been raised as
n issue [12]. Since early days of detection, an enormous diver-
ity has been exhibited by rotavirus in India [15,17–19]. A recent
eview from the subcontinent has revealed that the most common
 (G1–G4) and P-types (P [4] and P [8]) globally, accounted for
hree-fourths of all strains in this region [41]. It is worth noting that
he three vaccines that are relevant in the current debate, and vying
or inclusion in the national program, have included the following G
nd P combinations – Rotarix (G1P [8]), Rotateq (G1P1A [8], G2P1B
4], G3P1A [8], G4P1A [8] and G9P1A [8]), and Rotavac (G9P [11]).
otarix and Rotateq have been found to be safe in multiple pre-
icensure trials of these two vaccines [10,42,43]. Although, a low
isk of intussusception have been documented in post-licensure
tudies of Rotarix and Rotateq from some countries, such concern
s far outweighed by the health beneﬁts of vaccination [44,45].
.6. Immunization program issues
In 2010 the National Technical Advisory Group on Immuniza-
ion (NTAGI) played a key role in the development of the draft of
he National Vaccine Policy [46]. Established in August 2001 by the
epartment of Family Welfare, Government of India the NTAGI is
he primary advisory committee on all immunization related issues
n the country. The policy document observed that since the begin-
ing of the universal immunization program (UIP), India has had
ix major vaccine preventable diseases (tuberculosis, diphtheria,
etanus, pertussis, polio, and measles) under its ambit for more
han two decades (Fig. 1). Importantly, this document identiﬁed
 major hurdle; the lack of indigenous surveillance data to assess
isease burden to make decisions on the introduction of new vac-
ines. However, as shown earlier, data on morbidity and mortality
stimates for rotavirus disease in the country are now available
22,24–26,29–31].
We  encountered publications [46–48] relating to criteria for
olicy decision making in our search. Disease burden, safety and
fﬁcacy of the vaccine, affordability and ﬁnancial sustainability of
 proposed vaccination program, program capacity to introduce
ew vaccines (including cold chain capacity), vaccine production
apacity and cost effectiveness were the key issues [46]. In a rec-
mmendation paper, the Indian Academy of Pediatrics Committee
n Immunization (IAPCOI) [48] mentioned the use of evidence
ased methodology such as Grades of Recommendation Assess-
ent, Development and Evolution (GRADE). However, we  could
ot identify an evidence based policy framework in any program
ocument that could guide the introduction of rotavirus vaccine
n the Indian UIP. Moreover, as highlighted by Nelson and Walker
49], although NTAGI has discussed suitability of rotavirus vaccine
n India, no recommendation has yet been made. Meanwhile, critics
f the Indian immunization program have highlighted the country’s
nability to cope with the growing gap between demand and supply
f UIP vaccines [50]. It has also been mentioned that vaccine man-
facturers have been using trends observed in western countries
bout introducing new vaccines to inﬂuence India’s decision [50].
Another major challenge of India’s UIP is that fewer than 44%
f 27 million newborns in the country receive the full schedule of
accines [51]. Only 52% receive three doses of diphtheria-tetanus-
ertussis (DPT). Further, India spends woefully little on routine
mmunization [52]. Against this backdrop, critics have argued that
ndia’s ﬁrst priority should be ensuring access to inexpensive UIP
accines by the poor [7]. On the other hand, public debate on India’s
oor immunization performance is also lacking. The economists
aising this issue have further pointed out the futility of public inter-
entions until children reach school going age, although the ﬁrst (2014) A162–A170 A167
two years of life have a decisive and lasting inﬂuence on child’s
health, well-being, aptitude and opportunities. While explaining
such situation, they use the analogy of a gardener allowing anyone
to trample on ﬂowers in his garden and later trying to rectify the
neglect by giving the plants extra care and heavy doses of water
and fertilizer [53].
3.7. Economic issues – interfacing with immunization program
performance
In any vaccine policy discussion, economic issues play major role
[54]. Those opposing introduction of rotavirus vaccine in India’s UIP
highlighted that the number needed to be vaccinated for preven-
ting one death and the cost incurred in doing so would considerably
exceed per capita income in India, if vaccines produced by multi-
national companies are used [55]. Furthermore, external ﬁnancial
assistance over a limited period of time extended to the develop-
ing countries like India for introducing newer vaccines have been
mentioned by this group as a way to lure these countries into
a ‘debt-trap’ [56]. Development of indigenous [57] and low-cost
(∼INR 180 for 3 doses/child) [8] Rotavac blunts the above argu-
ments.
Regarding economic burden, one study pegged the direct hos-
pitalization related costs to families to be between INR 1530 and
3130 [58]. Another reports that the median direct medical costs
due to rotavirus hospitalization in India varies from INR 1800 to
4300 (dependent on the level of care) while the overall economic
burden due to rotavirus in India has been calculated in the range
of INR 2–3.4 billion [22]. Considering the above ﬁgures, it has been
projected that a rotavirus vaccination program in India, even at
50% efﬁcacy, would prevent around 44,000 deaths, 293,000 hos-
pitalizations and 328,000 outpatient visits annually, and would
save the national exchequer more than US$ 20 million (∼INR 860
million) per year (as per 2008 rates) in the cost of medical treat-
ment [59]. In order to predict the economic impact of introducing
rotavirus vaccine in the national immunization program in India,
researchers considered factors such as disease burden, vaccine
efﬁcacy and vaccine cost. Two  studies [59,60] reaching similar con-
clusions envisaged that rotavirus vaccine would likely be a good
investment in the country.
Rheingans et al. [61] raised the issues of distributional effects
and equity concerns. Their work revealed that the Indian states
with the lowest cost effectiveness ratio (CER) – a favorable situation
– are those with high pre-vaccination mortality. However, many
of these states will also have the lowest proportional reduction
in rotavirus mortality due to low vaccination coverage. If national
rotavirus vaccination were implemented in India within the exist-
ing immunization coverage, then the states with the most favorable
CERs and greatest disease burden would beneﬁt the least. Their
analysis also suggests that the value for money of rotavirus vacci-
nation could be substantially increased by eliminating differences
in coverage between richest and poorest quintiles; the number of
deaths averted would increase by 89% among the poorest quintile
and could increase the overall number of lives saved by 38%. This
is equivalent to increasing vaccine efﬁcacy against severe rotavirus
infection from 57% to 79% [61].
4. Discussion
In this discourse, we have critically examined the debate on
whether rotavirus vaccine should be introduced in India’s immu-
nization program. Our intent was to identify how arguments used
by pro- and anti-vaccine lobbies could inform a policy decision pro-
cess. While both sides have used epidemiological data, economic
arguments, and clinical trial results, we  could locate very few
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eferences pertaining to challenges in translating these evidences
nto action. A description of policy making processes for any
accine currently used in the national immunization program was
lso scarce.
The ﬁrst moot point we identiﬁed was if the public health prob-
em surrounding rotavirus morbidity was being overestimated.
t has been argued that bacterial and parasitic co-infections in
he gut are actually responsible for severity of rotavirus diarrhea
ncountered in our setting [12,62]. In order to obtain clinching bio-
ogical evidence in this regard, one needs to know which of the
ut organisms had harmless presence, which increased the severity
f diarrhea and which one was responsible for primary causation.
he Global Enteric Multicenter Study (GEMS) focusing on the eti-
logy and population-based burden of pediatric diarrheal diseases
n sub-Saharan Africa and south Asia has thrown some light on this
ssue by identifying that rotavirus was the most common cause of
oderate-to-severe diarrhea at every study site during ﬁrst year of
ife [27]. It is also important to know that rotavirus vaccines in clin-
cal trials have shown efﬁcacy in reducing ‘diarrhea of any severity’
nd ‘SRVGE’. A policy making body may  not have answers to all the
uestions, cited in this paragraph, at a given point in time but they
an work under the principle that policy evolves through a process
nd is not a one-time event [63].
Secondly, the failure of vaccine uptake by the gut mucosa of
 child due to anti-rotavirus antibodies in breast milk of mothers
nd the inability of natural rotavirus infections in preventing sub-
equent infections (reported from south India) were host related
oncerns. Preliminary evidence suggests that breastfeeding might
ot interfere with the immunogenicity of orally administered live
ttenuated rotavirus vaccines in a clinically signiﬁcant way [64,65].
urther investigations are ongoing in this area. It is worth mention-
ng that not only chance of reinfection but also severity of diarrhea
as been found to decrease following ﬁrst infection with rotavirus
n north India and abroad [35,36]. The goal that has been pursued to
evelop live oral rotavirus vaccines [66] is to duplicate the degree of
rotection against the disease (effect) that follows natural infection
67]. Corroboration regarding reduction in severity of rotavirus gas-
roenteritis following vaccination has been obtained through clin-
cal trials from Bangladesh and Vietnam [11]. Further supportive
vidence come from Mexico and Brazil [68,69], which have wit-
essed reduction in childhood mortality and hospitalizations due
o diarrheal disease – mostly noted among children under two  years
ge – following introduction of rotavirus vaccine. As a proactive pol-
cy making process needs to draw evidences from multiple sources,
ost of the above evidence favors introducing rotavirus vaccine.
Macro-social environmental issues constitute another area of
iscussion. Infrastructural development is favored over rotavirus
accine by some as, presumably, such interventions would reduce
iarrheal morbidity and mortality, including those caused by
otavirus. We maintain that policy making often takes place in
n environment of incomplete empirical evidence. For instance,
vidence on effectiveness of improved sanitation, hygiene and pro-
ision of safe water in controlling rotavirus diarrhea [12,38] may
ot be available in the immediate future. We  emphasize, ‘introduc-
ion of rotavirus vaccine in national immunization program in India’
nd ‘infrastructural development ensuring sanitation, hygiene and
afe water’ should not be pitched against each other as these agenda
re not mutually exclusive. While the former is necessary to fulﬁll
he immediate goal of reducing rotavirus induced morbidity and
ortality in children under-ﬁve, the other will pay dividends in
he long-run. As indicated by Anderson et al. [70], it is unrealistic
o demand that every decision be based on robust scientiﬁc evi-
ence, especially when we know that we are far from having all
he information we need.
Many live oral vaccines often elicit reduced immunogenic-
ty when administered in a developing nation, compared to (2014) A162–A170
industrialized country settings [71]. This has also been the
case with rotavirus vaccines [72,73]. Reasons for this reduced
immune response is yet to be clearly understood, although tropical
enteropathy, characterized by intestinal inﬂammation, blunting
of small intestinal villi, and mal-absorption, along with poor
nutrition have been hypothesized as potential causes [74]. While
reduced efﬁcacy due to the above reasons is a reality, work of
Rheingans et al. [61] who considered a vaccine efﬁcacy as low as
50%, revealed that a considerable proportion of birth cohort of 27
million children will beneﬁt from introduction of rotavirus vaccine
in India. Apart from efﬁcacy and immunogenicity, safety plays a
critical role in the considerations of any vaccine. Available evidence
does not warrant against introduction of rotavirus vaccine in the
national program from this perspective.
Lack of public debate [53] on India’s poor immunization perfor-
mance [75] is an issue under the macro-social environment that has
been highlighted. Discussion on utility of rotavirus vaccines in India
has remained mostly restricted to public health professionals and
clinicians. Although, we could locate studies on pediatricians’ per-
ceptions and practices about rotavirus vaccine, qualitative studies
on mother’s perceptions were lacking. Such investigations should
be promoted through committed resources and the ﬁndings incor-
porated in vaccine policy discussion. The current NTAGI of India
[76] does not have public representation in it. This gap also needs
to be bridged at the earliest.
Whether rotavirus serotype-speciﬁc neutralizing antibodies
(immunity) play an important role in protection against rotavirus-
associated diarrhea is still under discussion. The goal that has been
pursued to develop rotavirus vaccines is to duplicate the degree
of protection against disease that follows natural infection [67].
Although, some have opined that serotype speciﬁc immunity [77]
is of central importance, recent evidence from clinical trials and
post-licensure studies indicate protection against a wide range of
circulating rotavirus strains, even those not included in the vac-
cine [78–81]. However, monitoring ‘strain shift’ in the community
should be continued in India during post-vaccination period so that
the range of protection offered by rotavirus vaccines through the
national program can be tracked [20].
Finally, it needs to be appreciated that health in India is a
state subject. Heterogeneity exists among Indian states in terms
of immunization program performance, and it is estimated that
the poorly performing states with low immunization coverage will
draw less beneﬁt from introduction of rotavirus vaccines [61]. A
pragmatic decision making paradigm is, thus, required in such an
environment of heterogeneity. The states which are currently in
a position to reap the beneﬁt of rotavirus vaccine should not be
restrained from doing so. Meanwhile, poorly performing states
should step up their vaccination program. The latter goal should
however not be the basis of delaying introduction of rotavirus
vaccine in the national immunization program, and may even be
considered unethical. Availability of a low-cost indigenous vaccine
further strengthens this issue as it would lead to reduced ﬁnancial
burden to the exchequer [82].
Synthesis of evidence within an ethical and rights-based per-
spective thus led us to conclude that introduction of rotavirus
vaccine is justiﬁed. Otherwise, the cost of inaction could be over-
whelmingly large in the future, compared to the cost of action
today. One, of course, needs to evaluate the impact of such a policy
decision at regular intervals, and ensure public engagement in the
process.Conﬂict of interest
The authors declare that they had no competing interests that
could have inappropriately inﬂuenced this study.
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